Condition
Uterine Carcinoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06369155Phase 2Recruiting
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT07435987Not ApplicableNot Yet Recruiting
Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy
NCT04030000Phase 1WithdrawnPrimary
Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation
Showing all 3 trials